$4.3 Million Diamond-Encrusted High Heels on Offer in Shanghai
(Bloomberg) -- Back in the 1980s, Paul Simon and Ladysmith Black Mambazo sang of a rich woman in New York so glamorous she had diamonds on the soles of her shoes. Now famed shoe designer Jimmy Choo is betting her contemporaries are in China.
At a giant trade fair under way in Shanghai, Choo and fellow designer Reggie Hung are showing off gemstone shoes for Chinese one-percenters. Choo and Hung's top-of-the-line model: a pair of high heels inlaid with thousands of rare pink diamonds with a $4.3 million price tag.
The shoes are the most expensive piece presented by Gènavant, the two designers' London-based luxury brand that's using the China International Import Expo in Shanghai to launch its bling footwear in China, according to Managing Director Tao Xiao.
Even as China's economic growth slows, some of the country's wealthiest consumers still are willing to shell out for conspicuous luxury goods from brands like Gènavant. Choo and Hung's company, which makes its shoes in Italy and then adds the gemstones in Taiwan, has already received orders, Tao said.
If paying more than $4 million for a pair of shoes is beyond your reach, not to worry. Gènavant also offers shoes with a starting price of $50,000 for consumers on a more modest budget.
To contact Bloomberg News staff for this story: Bruce Einhorn in Hong Kong at beinhorn1@bloomberg.net
To contact the editors responsible for this story: K. Oanh Ha at oha3@bloomberg.net, Jeff Sutherland
©2018 Bloomberg L.P.
With assistance from Editorial Board
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.